CART has clinical trials that are prevention trials for cognitively normal older adults and symptomatic clinical trials for older adults with a diagnosis of mild cognitive impairment or dementia due to Alzheimer’s Disease (AD). These studies involve a treatment. Please see below.
Cognitively Normal / Family History / APOE Genes
No studies enrolling at this time
Diagnosis of Mild Cognitive Impairment (MCI) / Mild Dementia Due to Alzheimer’s Disease (AD)
CART conducts observational studies that do not involve a treatment. These studies vary for time commitment and typically include: memory testing, blood draws and sometimes imaging (MRI/PET). Observational studies help us understand aging and Alzheimer’s disease.
More information coming soon!
Enrollment open only for people who don’t qualify for AHEAD preventative study. To learn about other research opportunities, click Research Interest.
More information about the study can be found APEX-clinicaltrails.gov.
More information coming soon!
Enrollment open only for people currently and/or have served in clinical trials. To learn about other research opportunities, click Research Interest.
Be on the lookout for updates on our upcoming studies. We are currently awaiting approval to get up and running!
Cognitively Normal / Family History / APOE Genes
More information coming soon!
Some study information can be found INSERT LINK.
Enrollment opening soon. Click Research Interest to complete an interest form.
Diagnosis of Mild Cognitive Impairment (MCI) / Mild Dementia due to Alzheimer’s Disease (AD)
No upcoming trials at this time.
More information coming soon!
More information about the study can be found at ADNI4-clinicaltrials.gov.
Enrollment opening soon. To learn about research opportunities, click Research Interest.
These studies are currently being run at CART but are closed to enrollment for new participants.
The AHEAD study will look at whether an investigational treatment, Lecanemab (also called BAN2401), is safe and effective in delaying the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life.
The AHEAD study, which aims to help prevent Alzheimer’s disease, is testing whether an investigational treatment delays memory decline in people up to 20 years before symptoms appear.
The AHEAD study is the first trial that aims to prevent Alzheimer’s by enrolling participants as young as 55, using tailored dosing of an investigational treatment.
The AHEAD study is comprised of two different clinical trials testing the same investigational treatment (Lecanemab) in people who may be at risk for memory problems. Participants will receive a tailored dose of the study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one for the two AHEAD trials based on the level of amyloid in their brain:
More general information about this study can be found at AHEAD-clinicaltrials.gov. More study-specific information can be found at AHEAD Study
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
The Clarity study is assessing the safety, tolerability and effectiveness of BAN2401 a monoclonal antibody (passive vaccine). This investigational new medication is being evaluated to understand if it can stop or reduce the buildup of amyloid in the brain and potentially stop or slow the progression of symptoms of disease progression in individuals living with AD.
To learn more about this study please click Clarity-clinicaltrials.gov
FDA full approval granted, follow Lecanemab FDA Approval to see!
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
In this study, we are trying to understand if an investigational drug called MIB-626 has the potential to be beneficial to individuals with Alzheimer’s disease. MIB-626 contains beta-nicotinamide mononucleotide, which is a naturally-occurring nutrient similar to Vitamin B3. It is found in all living things, including your own body. The study will allow us to determine the safety and efficacy of MIB-626 and help to establish whether it can be used in the future for Alzheimer’s disease prevention.
Click Research Interest to complete an interest form.
The AHEAD study will look at whether an investigational treatment, Lecanemab (also called BAN2401), is safe and effective in delaying the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life.
The AHEAD study, which aims to help prevent Alzheimer’s disease, is testing whether an investigational treatment delays memory decline in people up to 20 years before symptoms appear.
The AHEAD study is the first trial that aims to prevent Alzheimer’s by enrolling participants as young as 55, using tailored dosing of an investigational treatment.
The AHEAD study is comprised of two different clinical trials testing the same investigational treatment (Lecanemab) in people who may be at risk for memory problems. Participants will receive a tailored dose of the study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one for the two AHEAD trials based on the level of amyloid in their brain:
More general information about this study can be found at AHEAD-clinicaltrials.gov.
More study-specific information can be found at AHEAD Study
This study is currently enrolling. Click AHEAD Interest to complete an interest form.
The Clarity study is assessing the safety, tolerability and effectiveness of BAN2401 a monoclonal antibody (passive vaccine). This investigational new medication is being evaluated to understand if it can stop or reduce the buildup of amyloid in the brain and potentially stop or slow the progression of symptoms of disease progression in individuals living with AD.
To learn more about this study please click Clarity-clinicaltrials.gov
FDA full approval granted, follow Lecanemab FDA Approval to see!
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information coming soon!
More information about the study can be found at ADNI4-clinicaltrials.gov.
Enrollment opening soon. To learn about research opportunities, click Research Interest.
More information coming soon!
Enrollment opening soon. To learn about research opportunities, click Research Interest.
More information about the study can be found Learn-clinicaltrails.gov .
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information about the study can be found at Learn-clinicaltrails.gov.
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
The Trial Ready Cohort (TRC) study is to build a large group, or “cohort”, of individuals who are interested in being recruited into clinical trials aimed at reducing the risk of developing AD dementia. To do this, we will collect data from cognitively normal or minimally impaired individuals and then inform them if a trail may be appropriate for them.
More information about the study can be found Trc-PAD-clinicaltrials.gov.
This study is currently enrolling. Click Research Interest to complete an interest form.
More information coming soon!
More information about the study can be found Celia-clinicaltrials.gov.
Enrollment opening soon. Click Research Interest to complete an interest form.
In this study, we are trying to understand if an investigational drug called MIB-626 has the potential to be beneficial to individuals with Alzheimer’s disease. MIB-626 contains beta-nicotinamide mononucleotide, which is a naturally-occurring nutrient similar to Vitamin B3. It is found in all living things, including your own body. The study will allow us to determine the safety and efficacy of MIB-626 and help to establish whether it can be used in the future for Alzheimer’s disease prevention.
More information coming soon!
More information about the study can be found START-clinicaltrials.gov
Enrollment opening soon. Click Research Interest to complete an interest form.
More information coming soon!
More information about the study can be found Trailblazer-clinicaltrials.gov.
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information coming soon!
More information about the study can be found at ADNI4-clinicaltrials.gov.
Enrollment opening soon. To learn about research opportunities, click Research Interest.
The AHEAD study will look at whether an investigational treatment, Lecanemab (also called BAN2401), is safe and effective in delaying the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life.
The AHEAD study, which aims to help prevent Alzheimer’s disease, is testing whether an investigational treatment delays memory decline in people up to 20 years before symptoms appear.
The AHEAD study is the first trial that aims to prevent Alzheimer’s by enrolling participants as young as 55, using tailored dosing of an investigational treatment.
The AHEAD study is comprised of two different clinical trials testing the same investigational treatment (Lecanemab) in people who may be at risk for memory problems. Participants will receive a tailored dose of the study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one for the two AHEAD trials based on the level of amyloid in their brain:
More general information about this study can be found at AHEAD-clinicaltrials.gov.
More study-specific information can be found at AHEAD Study
This study is currently enrolling. Click AHEAD Interest to complete an interest form.
In this study, we are trying to understand if an investigational drug called MIB-626 has the potential to be beneficial to individuals with Alzheimer’s disease. MIB-626 contains beta-nicotinamide mononucleotide, which is a naturally-occurring nutrient similar to Vitamin B3. It is found in all living things, including your own body. The study will allow us to determine the safety and efficacy of MIB-626 and help to establish whether it can be used in the future for Alzheimer’s disease prevention.
The Trial Ready Cohort (TRC) study is to build a large group, or “cohort”, of individuals who are interested in being recruited into clinical trials aimed at reducing the risk of developing AD dementia. To do this, we will collect data from cognitively normal or minimally impaired individuals and then inform them if a trail may be appropriate for them.
More information about the study can be found Trc-PAD-clinicaltrials.gov.
This study is currently enrolling. Click Research Interest to complete an interest form.
The Clarity study is assessing the safety, tolerability and effectiveness of BAN2401 a monoclonal antibody (passive vaccine). This investigational new medication is being evaluated to understand if it can stop or reduce the buildup of amyloid in the brain and potentially stop or slow the progression of symptoms of disease progression in individuals living with AD.
To learn more about this study please click Clarity-clinicaltrials.gov
FDA full approval granted, follow Lecanemab FDA Approval to see!
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information coming soon!
More information about the study can be found Trailblazer-clinicaltrials.gov.
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information about the study can be found at Learn-clinicaltrails.gov.
This study is closed to enrollment. To learn about other research opportunities, click Research Interest.
More information coming soon!
More information about the study can be found Celia-clinicaltrials.gov.
Enrollment opening soon. Click Research Interest to complete an interest form.
More information coming soon!
More information about the study can be found START-clinicaltrials.gov
Enrollment opening soon. Click Research Interest to complete an interest form.
More information coming soon!
More information about the study can be found at ADNI4-clinicaltrials.gov.
Enrollment opening soon. To learn about research opportunities, click Research Interest.
More information coming soon!
Enrollment opening soon. To learn about research opportunities, click Research Interest.
More information about the study can be found Learn-clinicaltrails.gov .
60 Fenwood Road
Hale Building for Transformative Medicine
Boston, MA 02115
Email: cart@mgb.org
Phone: (617) 732-8085
Fax: (617) 264-6831
© Brigham & Women's Hospital. 2025 All Rights Reserved.
